Onconova Therapeutics (NASDAQ:ONTX) issued its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($1.29) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.11) by ($0.18), MarketWatch Earnings reports. Onconova Therapeutics had a negative return on equity of 336.39% and a negative net margin of 1,675.33%. The business had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.08 million.
Shares of ONTX stock traded down $0.23 during mid-day trading on Wednesday, reaching $3.93. The stock had a trading volume of 6,839 shares, compared to its average volume of 43,217. Onconova Therapeutics has a 52-week low of $1.69 and a 52-week high of $11.17. The stock has a market capitalization of $25.35 million, a price-to-earnings ratio of -0.79 and a beta of 2.95.
ONTX has been the subject of a number of recent analyst reports. Zacks Investment Research downgraded Onconova Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 16th. ValuEngine downgraded shares of Onconova Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, February 2nd. HC Wainwright restated a “buy” rating and issued a $25.00 price objective on shares of Onconova Therapeutics in a research report on Friday, February 8th. Finally, Maxim Group restated a “buy” rating and issued a $16.00 price objective on shares of Onconova Therapeutics in a research report on Monday, March 25th.
Onconova Therapeutics Company Profile
Onconova Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule product candidates to treat cancer. Its product candidates include Rigosertib IV, which is in Phase III clinical trial for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trial for patients with higher-risk MDS; and Rigosertib oral, which is in Phase II clinical trial for patients with lower risk MDS.
Further Reading: Real Estate Investment Trust (REIT) ETF
Receive News & Ratings for Onconova Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconova Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.